2025年小干扰核糖核酸（RNA）全球市场报告

近年来，小干扰核糖核酸（siRNA）市场呈现指数级成长，预计将从2024年的156.5亿美元成长到2025年的188.6亿美元，复合年增长率达20.5%。过去几年的成长可归因于政府投入的增加、人们对遗传疾病认识的提高、小干扰核糖核酸（siRNA）疗法临床试验的扩大、生物技术基础设施的扩展以及标靶治疗的日益普及。

预计未来几年，小干扰RNA（siRNA）市场将呈指数级增长，到2029年市场规模将达到392.6亿美元，复合年增长率（CAGR）为20.1%。预测期内的增长可归因于个性化医疗需求的不断增长、siRNA研究投资的增加、製药公司间合作的加强以及基于siRNA的药物核准数量的增加。预测期内的关键趋势包括递送方法的技术进步、RNAi疗法的创新、脂质奈米颗粒载体的开发、基因静默的研究与开发以及标靶药物递送系统的进步。

预计未来几年，对个人化医疗日益增长的需求将推动siRNA市场的成长。个人化医疗是一种根据患者的遗传、环境和生活方式因素量身定制治疗方法的方法，旨在优化治疗效果并改善患者护理。基因组学技术的进步使得精准识别基因突变和个人化治疗成为可能，从而提升了市场需求。小干扰RNA（siRNA）透过标靶基因静默为个人化医疗提供支持，使其适用于治疗特定的遗传性疾病。 siRNA透过选择性抑制致病mRNA，最大限度地减少脱靶效应，从而提高治疗效果和患者预后。例如，根据美国非营利组织「个人化医疗联盟」（Personalized Medicine Alliance）统计，截至2024年2月，美国食品药物管理局（FDA）在2023年核准了26种新的个人化药物，较2022年的12种显着成长。因此，对个人化医疗日益增长的需求正在推动小干扰RNA（siRNA）市场的成长。

小干扰RNA（siRNA）疗法市场的主要企业正在寻求监管部门核准其治疗罕见遗传疾病的新机制，旨在提供持久疗效并减少给药频率。监管部门核准是指正式授权，允许治疗方法安全地进行测试、上市或用于患者。例如，2025年3月，美国生物製药公司Alnylam Pharmaceuticals, Inc.的Qfitlia（fitusiran）获得了美国食品药物管理局（FDA）的核准。 Qfitlia是第一个以siRNA为基础的治疗方法，适用于12岁以上患有A型或B型血友病（伴或不伴阻碍要素）的成人和青少年患者。该疗法旨在降低抗凝血酵素水平并促进凝血酶生成，从而促进血液凝固并减少出血事件。 Qfitlia采用每两个月一次的皮下注射给药方案，为血友病治疗提供了一种新型的非因子治疗选择。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球小干扰核糖核酸（RNA）：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
• 终端用户产业分析
• 全球小干扰核糖核酸（RNA）市场：成长率分析
• 全球小干扰核糖核酸（RNA）市场表现：规模与成长，2019-2024年
• 全球小干扰核糖核酸（RNA）市场预测：规模与成长，2024-2029年，2034年预测
• 全球小干扰核糖核酸（RNA）：潜在市场规模（TAM）

第六章 市场细分

• 全球小干扰核糖核酸 (RNA) 市场按类型、表现和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 脂质体全身疗法
• 基于奈米颗粒的全身性治疗
• 全球小干扰核糖核酸 (RNA) 市场：按适应症、表现和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 心血管疾病
• 呼吸系统疾病
• 肿瘤学
• 神经退化性疾病
• 感染疾病
• 全球小干扰核糖核酸 (RNA) 市场按最终用户、性能和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测
• 医院
• 研究所
• 製药和生物技术公司
• 学术机构
• 全球小干扰核糖核酸 (RNA) 市场：按脂质体系统疗法、类型、性能和预测进行细分，2019-2024 年、2024-2029 年预测、2034 年预测
• 阳离子脂质体递送
• 中性脂质体递送
• 聚乙二醇化脂质体递送
• 标靶化脂质体递送
• 全球小干扰核糖核酸 (RNA) 市场：按奈米颗粒系统疗法、类型、性能和预测进行细分，2019-2024 年、2024-2029 年预测、2034 年预测
• 脂质奈米颗粒递送
• 聚合物奈米颗粒递送
• 金奈米颗粒递送
• 二氧化硅奈米颗粒递送

第七章 区域和国家分析

• 全球小干扰核糖核酸（RNA）市场：区域分析、预测与成长，2019-2024年、2024-2029年预测、2034年预测
• 全球小干扰核糖核酸 (RNA) 市场：按国家、表现和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

• 小干扰核糖核酸（RNA）市场：竞争模式
• 小干扰核糖核酸（RNA）市场：公司概况
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Wave Life Sciences Ltd.
• Silence Therapeutics plc
• Arrowhead Pharmaceuticals Inc.
• Quark Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Evox Therapeutics Ltd.
• Phio Pharmaceuticals Inc.
• Genecon Biotechnologies Co., Ltd.
• Olix Pharmaceuticals, Inc.
• Benitec Biopharma Ltd.
• Bio-Path Holdings, Inc.
• Calando Pharmaceuticals, Inc.
• Sirnaomics, Ltd.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

• 2029年小干扰核糖核酸（RNA）市场：提供新机会的国家
• 小干扰核糖核酸（RNA）市场展望 2029：新兴细分市场机会
• 小干扰核糖核酸 (RNA) 市场 2029 年：成长策略
  • 基于市场趋势的策略
  • 竞争对手策略

第36章附录

Small interfering ribonucleic acid (RNA) is a short, double stranded RNA molecule that plays a key role in gene silencing through a process called RNA interference (RNAi). It binds to complementary messenger RNA (mRNA) sequences, causing their degradation and preventing protein synthesis. The primary purpose of siRNA is to regulate or suppress the expression of specific genes, and it is often used in research and therapeutic applications to target disease causing genes.

The main types of small interfering ribonucleic acid (RNA) include liposome systemic therapy and nanoparticle based systemic therapy. Liposome systemic therapy is a drug delivery method that uses liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are indicated for conditions such as cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, serving end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The small interfering ribonucleic acid (RNA) market research report is one of a series of new reports from the business research company that provides small interfering ribonucleic acid (RNA) market statistics, including small interfering ribonucleic acid (RNA) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (RNA) market share, detailed small interfering ribonucleic acid (RNA) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (RNA) industry. This small interfering ribonucleic acid (RNA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small interfering ribonucleic acid (RNA) market size has grown exponentially in recent years. It will grow from $15.65 billion in 2024 to $18.86 billion in 2025 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to rising government funding, increasing awareness of genetic disorders, growing clinical trials for small interfering ribonucleic acid (siRNA) therapies, expansion of biotechnology infrastructure, and rising adoption of targeted therapeutics. biotechnology infrastructure, and increasing adoption of targeted therapeutics.

The small interfering ribonucleic acid (RNA) market size is expected to see exponential growth in the next few years. It will grow to $39.26 billion in 2029 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to rising demand for personalized medicine, growing investment in small interfering ribonucleic acid (siRNA) research, increasing collaborations between pharma companies, and rising approvals of small interfering ribonucleic acid (siRNA) based drugs. Major trends in the forecast period include technological advancements in delivery methods, innovations in RNAi therapeutics, developments in lipid nanoparticle carriers, research and development in gene silencing, and advancements in targeted drug delivery systems.

The rising demand for personalized medicine is expected to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is an approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. Demand is increasing due to advancements in genomic technologies, which allow precise identification of genetic variations and enable customized treatments for individuals. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling targeted gene silencing, making it suitable for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, enhancing therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a US based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies in the small interfering ribonucleic acid (siRNA) therapeutics market are pursuing regulatory approvals for novel mechanisms to treat rare genetic diseases, aiming to provide sustained effects and reduce dosing frequency for patients. Regulatory approvals are official clearances that permit a therapy to be safely tested, marketed, or used in patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US based biopharmaceutical company, received approval from the U.S. Food and Drug Administration for Qfitlia (fitusiran), the first siRNA-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to lower antithrombin levels, enhancing thrombin generation to promote clot formation and reduce bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing regimen, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US based biopharmaceutical company, partnered with ADARx Pharmaceuticals Inc. Through this partnership, AbbVie aims to combine ADARx's proprietary RNA technology with its scientific expertise to develop next-generation siRNA therapies, advancing treatment in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company developing siRNA-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co., Ltd., Olix Pharmaceuticals, Inc., Benitec Biopharma Ltd., Bio-Path Holdings, Inc., Calando Pharmaceuticals, Inc., Sirnaomics, Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2024. The regions covered in small interfering ribonucleic acid (RNA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the small interfering ribonucleic acid (RNA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Interfering Ribonucleic Acid (RNA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small interfering ribonucleic acid (rna) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small interfering ribonucleic acid (rna) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small interfering ribonucleic acid (rna) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Liposome Systemic Therapy; Nanoparticle-Based Systemic Therapy
• 2) By Indication: Cardiovascular Diseases; Respiratory Diseases; Oncology; Neurodegenerative Diseases; Infectious Diseases
• 3) By End-User: Hospital; Research Institutions; Pharmaceutical And Biotechnology Companies; Academic Institutions
• Subsegments:
• 1) By Liposome Systemic Therapy: Cationic Liposome Delivery; Neutral Liposome Delivery; Pegylated Liposome Delivery; Targeted Liposome Delivery
• 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery; Polymer Nanoparticle Delivery; Gold Nanoparticle Delivery; Silica Nanoparticle Delivery
• Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sarepta Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Silence Therapeutics plc; Arrowhead Pharmaceuticals Inc.; Quark Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Evox Therapeutics Ltd.; Phio Pharmaceuticals Inc.; Genecon Biotechnologies Co., Ltd.; Olix Pharmaceuticals, Inc.; Benitec Biopharma Ltd.; Bio-Path Holdings, Inc.; Calando Pharmaceuticals, Inc.; Sirnaomics, Ltd.
• Countries:

Table of Contents

1. Executive Summary

2. Small Interfering Ribonucleic Acid (RNA) Market Characteristics

3. Small Interfering Ribonucleic Acid (RNA) Market Trends And Strategies

4. Small Interfering Ribonucleic Acid (RNA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Small Interfering Ribonucleic Acid (RNA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Small Interfering Ribonucleic Acid (RNA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Small Interfering Ribonucleic Acid (RNA) Market Growth Rate Analysis
• 5.4. Global Small Interfering Ribonucleic Acid (RNA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Small Interfering Ribonucleic Acid (RNA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Small Interfering Ribonucleic Acid (RNA) Total Addressable Market (TAM)

6. Small Interfering Ribonucleic Acid (RNA) Market Segmentation

• 6.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposome Systemic Therapy
• Nanoparticle-Based Systemic Therapy
• 6.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Diseases
• Respiratory Diseases
• Oncology
• Neurodegenerative Diseases
• Infectious Diseases
• 6.3. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Research Institutions
• Pharmaceutical And Biotechnology Companies
• Academic Institutions
• 6.4. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Liposome Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cationic Liposome Delivery
• Neutral Liposome Delivery
• Pegylated Liposome Delivery
• Targeted Liposome Delivery
• 6.5. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Nanoparticle-Based Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipid Nanoparticle Delivery
• Polymer Nanoparticle Delivery
• Gold Nanoparticle Delivery
• Silica Nanoparticle Delivery

7. Small Interfering Ribonucleic Acid (RNA) Market Regional And Country Analysis

• 7.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market

• 8.1. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Small Interfering Ribonucleic Acid (RNA) Market

• 9.1. China Small Interfering Ribonucleic Acid (RNA) Market Overview
• 9.2. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Small Interfering Ribonucleic Acid (RNA) Market

• 10.1. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Small Interfering Ribonucleic Acid (RNA) Market

• 11.1. Japan Small Interfering Ribonucleic Acid (RNA) Market Overview
• 11.2. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Small Interfering Ribonucleic Acid (RNA) Market

• 12.1. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Small Interfering Ribonucleic Acid (RNA) Market

• 13.1. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Small Interfering Ribonucleic Acid (RNA) Market

• 14.1. South Korea Small Interfering Ribonucleic Acid (RNA) Market Overview
• 14.2. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Small Interfering Ribonucleic Acid (RNA) Market

• 15.1. Western Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
• 15.2. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Small Interfering Ribonucleic Acid (RNA) Market

• 16.1. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Small Interfering Ribonucleic Acid (RNA) Market

• 17.1. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Small Interfering Ribonucleic Acid (RNA) Market

• 18.1. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Small Interfering Ribonucleic Acid (RNA) Market

• 19.1. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Small Interfering Ribonucleic Acid (RNA) Market

• 20.1. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market

• 21.1. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
• 21.2. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Small Interfering Ribonucleic Acid (RNA) Market

• 22.1. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Small Interfering Ribonucleic Acid (RNA) Market

• 23.1. North America Small Interfering Ribonucleic Acid (RNA) Market Overview
• 23.2. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Small Interfering Ribonucleic Acid (RNA) Market

• 24.1. USA Small Interfering Ribonucleic Acid (RNA) Market Overview
• 24.2. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Small Interfering Ribonucleic Acid (RNA) Market

• 25.1. Canada Small Interfering Ribonucleic Acid (RNA) Market Overview
• 25.2. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Small Interfering Ribonucleic Acid (RNA) Market

• 26.1. South America Small Interfering Ribonucleic Acid (RNA) Market Overview
• 26.2. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Small Interfering Ribonucleic Acid (RNA) Market

• 27.1. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Small Interfering Ribonucleic Acid (RNA) Market

• 28.1. Middle East Small Interfering Ribonucleic Acid (RNA) Market Overview
• 28.2. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Small Interfering Ribonucleic Acid (RNA) Market

• 29.1. Africa Small Interfering Ribonucleic Acid (RNA) Market Overview
• 29.2. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Company Profiles

• 30.1. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape
• 30.2. Small Interfering Ribonucleic Acid (RNA) Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Small Interfering Ribonucleic Acid (RNA) Market Other Major And Innovative Companies

• 31.1. Alnylam Pharmaceuticals Inc.
• 31.2. Ionis Pharmaceuticals Inc.
• 31.3. Wave Life Sciences Ltd.
• 31.4. Silence Therapeutics plc
• 31.5. Arrowhead Pharmaceuticals Inc.
• 31.6. Quark Pharmaceuticals Inc.
• 31.7. Arbutus Biopharma Corporation
• 31.8. Evox Therapeutics Ltd.
• 31.9. Phio Pharmaceuticals Inc.
• 31.10. Genecon Biotechnologies Co., Ltd.
• 31.11. Olix Pharmaceuticals, Inc.
• 31.12. Benitec Biopharma Ltd.
• 31.13. Bio-Path Holdings, Inc.
• 31.14. Calando Pharmaceuticals, Inc.
• 31.15. Sirnaomics, Ltd.

32. Global Small Interfering Ribonucleic Acid (RNA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market

34. Recent Developments In The Small Interfering Ribonucleic Acid (RNA) Market

35. Small Interfering Ribonucleic Acid (RNA) Market High Potential Countries, Segments and Strategies

• 35.1 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer